Back to today’s briefing

Story perspectives

Generate Biomedicines Raises $400M in Revitalizing IPO

2/28/2026

29 5 Full Breakdown

Summary

Story summary

Generate Biomedicines raised $400 million in an IPO on February 26, 2026, following collaborations with Amgen and Novartis.
The company sold 25 million shares at $16.
Trading is expected on Nasdaq under the ticker GENB.
Generate Biomedicines plans $300 million for GB-0895 Phase 3 in severe asthma and $100 million for COPD.
The IPO signals renewed biotech investor interest after 2025’s low activity.

History

Historical Context

The biotech sector saw a significant revival in 2020, with IPOs exceeding $10 billion, largely due to companies like Moderna and BioNTech. Following a 50% funding drop in 2025, Generate Biomedicines' $400 million IPO in 2026, supported by collaborations with Amgen and Novartis, underscores renewed investor confidence and a focus on innovative treatments for conditions like severe asthma and COPD.

1 of 2

Story summary

Generate Biomedicines raised $400 million in an IPO on February 26, 2026, following collaborations with Amgen and Novartis.
The company sold 25 million shares at $16.
Trading is expected on Nasdaq under the ticker GENB.
Generate Biomedicines plans $300 million for GB-0895 Phase 3 in severe asthma and $100 million for COPD.
The IPO signals renewed biotech investor interest after 2025’s low activity.

1 / 2